Athena Countouriotis - 16 Jun 2026 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Reporting relationship: Director
Issuer ticker: IOVA
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 17:16:26 UTC
Prior SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Athena Countouriotis

Key filing fact

Athena Countouriotis filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 18 Jun 2026.

Key facts

This page summarizes Athena Countouriotis's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 17:16.

Change

Previous filing in this sequence was filed on 04 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001571469 Primary reporting owner

Countouriotis Athena

Relationship: Director
Address: C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS
Signature: /s/ Athena Countouriotis
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOVA transaction Derivative

Deferred Restricted Stock Unit

Award

Transaction value
Shares: +90,316
Change %
Price: $0.000000^*
Shares after: 90,316
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,316
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

Footnote F2

Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.